Soundbites: Cost-Effectiveness Analysis
Scan brief descriptions of cost-effectiveness analyses conducted by our center community and our decision science colleagues across the globe.
![Image of Nicole Campos.](https://chds.hsph.harvard.edu/wp-content/uploads/2017/08/PS_20170427_JK_TenureCelebration-55.jpg)
Scaling Cancer Prevention
This analysis used decision analytic modeling to estimate the health impact, costs, and cost-effectiveness of scaling-up HPV vaccination and cervical cancer screening in 50 low- and lower-middle-income countries.
![Headshots of Allison Portnoy (top) and Nick Menzies (bottom)](https://chds.hsph.harvard.edu/wp-content/uploads/2023/01/PS_Portnoy-Menzies_Combo-Photo.jpg)
Investment Case for TB Vaccines
When providing guidance for investment decisions and vaccine roll-out, it is important to analyze cost effectiveness, health equity, and macroeconomic impact. A World Health Organization (WHO) report outlines this for new tuberculosis (TB) vaccines in 105 LMICs.
![Image of Stephen Resch Filming in the GHELI Studio.](https://chds.hsph.harvard.edu/wp-content/uploads/2017/08/PS_20161101_RDS-SR-studio-intro_C100a_001_FG_025.jpg)
Cost-Effectiveness Thresholds
Interventions that impose costs per DALY averted less than 3x and 1x GDP per capita are considered cost-effective and very cost-effective, respectively. This article explores the conceptual foundation and derivation of this threshold.